RLAY

Over the past six months, Relay Therapeutics' stock (RLAY) increased by 94.60% from March 24, 2026, to September 24, 2026, with its 52-week range being $6.03 to $20.75. As of September 28, 2026, the share price was $17.69, marking a 240.85% increase from September 29, 2025. Key events impacting the stock include the US FDA Breakthrough Therapy designation for zovegalisib in February 2026, a public offering in May 2026 that raised $296.8 million and extended the company's cash runway into 2029, and ongoing clinical data updates, such as the September 2026 highlight of zovegalisib's strong efficacy and tolerability. Additionally, the CFO sold approximately $350,000 worth of shares, and the company reported earnings and revenue surprises of 0.00% and -86.97% respectively for the quarter ended June 2026, with revenue decreasing by 48.30%.